These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

349 related items for PubMed ID: 19262441

  • 1. Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with amd after bevacizumab treatment.
    Roh MI, Kim HS, Song JH, Lim JB, Koh HJ, Kwon OW.
    Retina; 2009 Apr; 29(4):523-9. PubMed ID: 19262441
    [Abstract] [Full Text] [Related]

  • 2. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema.
    Roh MI, Kim HS, Song JH, Lim JB, Kwon OW.
    Ophthalmology; 2009 Jan; 116(1):80-6. PubMed ID: 19118699
    [Abstract] [Full Text] [Related]

  • 3. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.
    Chan WM, Lai TY, Chan KP, Li H, Liu DT, Lam DS, Pang CP.
    Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623
    [Abstract] [Full Text] [Related]

  • 4. Concentration of cytokines in age-related macular degeneration after consecutive intravitreal bevacizumab injection.
    Roh MI, Lim SJ, Ahn JM, Lim JB, Kwon OW.
    Graefes Arch Clin Exp Ophthalmol; 2010 May; 248(5):635-40. PubMed ID: 19997926
    [Abstract] [Full Text] [Related]

  • 5. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization.
    Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS.
    Am J Ophthalmol; 2006 Mar; 141(3):456-62. PubMed ID: 16490490
    [Abstract] [Full Text] [Related]

  • 6. Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study.
    dell'Omo R, Cassetta M, dell'Omo E, di Salvatore A, Hughes JM, Aceto F, Porcellini A, Costagliola C.
    Am J Ophthalmol; 2012 Jan; 153(1):155-61.e2. PubMed ID: 21861975
    [Abstract] [Full Text] [Related]

  • 7. Aqueous humor cytokine levels in patients with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration.
    Sakurada Y, Nakamura Y, Yoneyama S, Mabuchi F, Gotoh T, Tateno Y, Sugiyama A, Kubota T, Iijima H.
    Ophthalmic Res; 2015 Jan; 53(1):2-7. PubMed ID: 25472810
    [Abstract] [Full Text] [Related]

  • 8. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A.
    Retina; 2007 Jan; 27(4):432-8. PubMed ID: 17420694
    [Abstract] [Full Text] [Related]

  • 9. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [Abstract] [Full Text] [Related]

  • 10. Profile of intraocular immune mediators in patients with age-related macular degeneration and the effect of intravitreal bevacizumab injection.
    Agawa T, Usui Y, Wakabayashi Y, Okunuki Y, Juan M, Umazume K, Kezuka T, Takeuchi M, Yamauchi Y, Goto H.
    Retina; 2014 Sep; 34(9):1811-8. PubMed ID: 24801651
    [Abstract] [Full Text] [Related]

  • 11. Inflammatory cytokines in aqueous humor of patients with choroidal neovascularization.
    Miao H, Tao Y, Li XX.
    Mol Vis; 2012 Sep; 18():574-80. PubMed ID: 22419849
    [Abstract] [Full Text] [Related]

  • 12. Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration.
    Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, Ohji M.
    Retina; 2010 Sep; 30(7):1034-8. PubMed ID: 20616682
    [Abstract] [Full Text] [Related]

  • 13. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
    Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X, Tübingen Bevacizumab Study Group, Grisanti S.
    Ophthalmology; 2008 Oct; 115(10):1750-5, 1755.e1. PubMed ID: 18708261
    [Abstract] [Full Text] [Related]

  • 14. Vascular endothelial growth factor in the aqueous humour in eyes with myopic choroidal neovascularization.
    Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M.
    Acta Ophthalmol; 2011 Aug; 89(5):459-62. PubMed ID: 20102348
    [Abstract] [Full Text] [Related]

  • 15. Intravitreal bevacizumab and cytokine levels in major and macular branch retinal vein occlusion.
    Lim JW.
    Ophthalmologica; 2011 Aug; 225(3):150-4. PubMed ID: 21150231
    [Abstract] [Full Text] [Related]

  • 16. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations.
    Algvere PV, Steén B, Seregard S, Kvanta A.
    Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of changes in choroidal neovascularization secondary to age-related macular degeneration after anti-VEGF therapy using spectral domain optical coherence tomography.
    You JY, Chung H, Kim HC.
    Curr Eye Res; 2012 May; 37(5):438-45. PubMed ID: 22510011
    [Abstract] [Full Text] [Related]

  • 18. Implications of bevacizumab on vascular endothelial growth factor and endostatin in human choroidal neovascularisation.
    Tatar O, Shinoda K, Kaiserling E, Claes C, Eckardt C, Eckert T, Pertile G, Boeyden V, Scharioth GB, Yoeruek E, Szurman P, Bartz-Schmidt KU, Tuebingen Bevacizumab Study Group, Grisanti S.
    Br J Ophthalmol; 2009 Feb; 93(2):159-65. PubMed ID: 18838410
    [Abstract] [Full Text] [Related]

  • 19. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
    Muether PS, Hermann MM, Viebahn U, Kirchhof B, Fauser S.
    Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
    [Abstract] [Full Text] [Related]

  • 20. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
    Freeman WR, Kozak I, Yuson RM, Nigam N, Cheng L, Mojana F.
    Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.